Improving malaria treatment during pregnancy


Due to a shortage of safety data on pregnant women for most of the currently recommended malaria treatments, there are limited treatment options for this vulnerable population, particularly in the first trimester.


MMV is supporting studies to investigate the safety profile of DHA-PQP for treatment during pregnancy.

More information in an interview with Dr Rukhsana Ahmed, Postdoctoral Research Associate in Clinical Epidemiology, Liverpool School of Tropical Medicine, UK.